Welcome to the e-CCO Library!

P459 The impact of latent cytomegalovirus infection on the disease behaviour in patients with ulcerative colitis
Year: 2020
Source:

ECCO'20 Vienna

Authors:

P. Långvall1, C. Shi1, P. Karling2

Created: Thursday, 30 January 2020, 10:12 AM
P459: Change in the expression of SerpinE1, a potential new disease activity marker, reflects therapeutic response in Inflammatory Bowel Disease
Year: 2021
Source: ECCO'21 Virtual
Authors: Jójárt, B.(1);Molnár, T.(2);Szabó, V.(1);Varga, Á.(1);Resál, T.(3);Szántó, K.(3);Kata, D.(4);Földesi, I.(4);Molnár, T.(3);Maléth, J.(5);Farkas, K.(3);
Created: Wednesday, 2 June 2021, 4:12 PM
P459: High inadequate surveillance rates in colitis-associated advanced neoplasia: a multicenter retrospective cohort study
Year: 2022
Source: ECCO'22
Authors: Te Groen , M.(1);Derks , M.E.(1);Peters , C.P.(2);Dijkstra , G.(3);De Vries , A.C.(4);Römkens , T.E.(5);Horjus , C.S.(6);De Boer , N.K.(7);De Jong , M.E.(1);Nagtegaal , I.D.(8);Derikx , L.A.(1);Hoentjen , F.(1,9);
Created: Friday, 11 February 2022, 3:52 PM
P459: Hospitalization, use of biologics and surgery rates in inflammatory bowel diseases: a single-center comparative analysis between public and private healthcare systems in a tertiary unit from Latin America
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Zacharias, P.(1);Perussolo, M.(2);Magro, D.O.(3);Barauna, F.D.S.B.(2);KotzeMD- PhD, P.G.(4)*;
Created: Friday, 14 July 2023, 11:05 AM
P459: Obesity in patients with an ileoanal pouch due to ulcerative colitis is not associated with an increased risk for pouchitis
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Pfeffer-Gik T.*1, Fishman S.1, Godny L.1, Tulchinsky H.2, Dotan I.1

Created: Wednesday, 20 February 2019, 10:36 AM
P459: Persistent mesorectal inflammatory activity is associated with complications after proctectomy in Crohn’s disease
Year: 2018
Source: ECCO '18 Vienna
Authors:

E.J. de Groof1, J.H. van der Meer2,3*, P.J. Tanis1, J.R. de Bruyn2,3, O. van Ruler1, G.R. D'Haens3, G.R. van den Brink2,3,4, W.A. Bemelman1, M.E. Wildenberg2,3, C.J. Buskens1

Created: Thursday, 21 February 2019, 9:14 AM
P459: Risk of relapse after azathioprine discontinuation in inflammatory bowel disease patients in maintained remission
Year: 2016
Source: ECCO '16 Amsterdam
Authors:

M. Iborra*1, B. Navarro1, X. Cortes2, M. Boscá3, T. Blazquez1, J. Herreras1, G. Trejo3, B. Beltrán1, P. Nos1

Created: Friday, 22 February 2019, 9:49 AM
P459: Vedolizumab for the treatment of chronic pouchitis: the Edinburgh experience
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

S. Cesano*1,2, G. R. Jones2, P. W. Jenkinson2, A. G. Shand2, C. W. Lees2, I. D. Arnott2, N. Plevris2

Created: Friday, 22 February 2019, 9:41 AM
P460 Evaluation of potential mechanisms underlying the safety observations of filgotinib in clinical studies in rheumatoid arthritis
Year: 2020
Source:

ECCO'20 Vienna

Authors:

A. Clarke, J. Di Paolo, B. Downie, A. Meng, N. Mollova, Y. Yu, P. Han

Created: Thursday, 30 January 2020, 10:12 AM
P460: A Real-World Picture of Adverse Drug Reactions in Inflammatory Bowel Disease
Year: 2022
Source: ECCO'22
Authors: Lemos Garcia, J.(1);Rosa, I.(2);Saraiva, S.(2);Moleiro, J.(2);Claro, I.(2);
Created: Friday, 11 February 2022, 3:52 PM
P460: Biomarkers reflecting extracellular matrix turnover and inflammation can be used to monitor disease activity and treatment response in patients with Crohn’s disease undergoing infliximab induction therapy
Year: 2021
Source: ECCO'21 Virtual
Authors: Sorokina Alexdóttir, M.(1);Bourgonje, A.R.(2);Asser Karsdal, M.(1);Bay-Jensen, A.C.(1);Faber, K.N.(2);Loveikyte, R.(2);van Dullemen, H.M.(2);Visschedijk, M.C.(2);Festen, E.A.M.(2);Weersma, R.K.(2);Dijkstra, G.(2);Mortensen, J.H.(1);
Created: Wednesday, 2 June 2021, 4:12 PM
P460: Early use of therapeutic drug monitoring to individualize infliximab therapy in paediatric IBD: a multicentre prospective COHORT study
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Crowley E.*1, Carman N.1, Arpino V.1, Frost K.1, Ricciuto A.1, Sherlock M.2, Critch J.3, Mack D.4, Benchimol E.5, Jacobson K.6, Lawrence S.6, deBruyn J.7, El-Matary W.8, Otley A.9, Huynh H.10, Church P.1, Walters T.1, Griffiths A.1

Created: Wednesday, 20 February 2019, 10:36 AM
P460: Effect of fertility treatment on inflammatory bowel disease outcomes
Year: 2016
Source: ECCO '16 Amsterdam
Authors:

M. Bejaoui*, C. Landman, J. Kirchgesner, A. Bourrier, I. Nion-Larmurier, H. Sokol, L. Beaugerie, J. Cosnes, P. Seksik

Created: Friday, 22 February 2019, 9:49 AM
P460: Efficacy of ustekinumab in patients with anti-TNF refractory Crohn’s disease: data from a real-world study in Brazil
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

R. S. Parra*1, M. R. Feitosa1, O. Féres1, J. J. Ribeiro da Rocha1, J. M. F. Chebli2, L. Chebli2, E. R. Bertges2, T. N. F. Gomes3, O. Ambrogini Jr3, A. J. T. Alves Junior4, M. Lubini5

Created: Friday, 22 February 2019, 9:41 AM
P460: Impact of anti-TNFα exposure during pregnancy for maternal inflammatory bowel disease on serologic response to vaccination of exposed children
Year: 2018
Source: ECCO '18 Vienna
Authors:

D. Duricová1*, E. Dvorakova1, J. Kozeluhova2, P. Kohout3, K. Mitrova4, M. Durilova5, K. Zarubova4, O. Hradsky4, J. Bronsky4, N. Hradska6, E. Bronska6, N. Machkova1, V. Hruba1, M. Bortlik1, M. Lukas1, K. Malickova1, M. Lukas1

Created: Thursday, 21 February 2019, 9:14 AM
P460: Preoperative nutrition supplementation may prevent one-year endoscopic recurrence in Crohn's disease patients
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Inniss, S.(1,2)*;Simpson, K.(1);Fragkos, K.(1);Wood, C.(1);Smith, A.(2);Rahman, F.(1,2);
Created: Friday, 14 July 2023, 11:05 AM
P461 Intolerance to 5-aminosalicylate is a risk of poor prognosis in ulcerative colitis patients
Year: 2020
Source:

ECCO'20 Vienna

Authors:

T. Fujii1, S. Hibiya1, C. Maeyashiki2, E. Saito1, K. Takenaka1, M. Motobayashi1, H. Shimizu1, M. Nagahori1, K. Ohtsuka1, M. Kurosaki2, T. Yauchi3, M. Watanabe1

Created: Thursday, 30 January 2020, 10:12 AM
P461: Clinical benefit of adalimumab after surgery in the treatment of complex perianal Crohn’s disease: a tertiary referral centre experience
Year: 2016
Source: ECCO '16 Amsterdam
Authors:

G. Solina*1, S. Renna2, E. Orlando2, M. Affronti2, M. Cottone2, A. Orlando2

Created: Friday, 22 February 2019, 9:49 AM
P461: Comparison of efficacy of different oral 5-aminosalicylic acid doses for maintenance of remission in ulcerative colitis: a systematic review and meta-analysis
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Choi C.H.*1, Kim Y.S.2, Moon W.3, Lee B.I.4, Kim E.S.5, Jung Y.6, Park D.I.7, Yoon Y.S.8, Lee H.9, Han D.S.10

Created: Wednesday, 20 February 2019, 10:36 AM
P461: COVID-19 outcomes in patients receiving anti-TNF treatments: A systematic review and meta-analysis
Year: 2022
Source: ECCO'22
Authors: Kokkotis, G.(1);Kitsou, K.(2);Xynogalas, I.(3);Spoulou, V.(2);Magiorkinis, G.(4);Poulakou, G.(3);Syrigos, K.(3);Bamias, G.(1);
Created: Friday, 11 February 2022, 3:52 PM